MX387115B - Métodos para tratar la influenza. - Google Patents

Métodos para tratar la influenza.

Info

Publication number
MX387115B
MX387115B MX2019009443A MX2019009443A MX387115B MX 387115 B MX387115 B MX 387115B MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 387115 B MX387115 B MX 387115B
Authority
MX
Mexico
Prior art keywords
methods
treating influenza
prevention
treatment
relates
Prior art date
Application number
MX2019009443A
Other languages
English (en)
Other versions
MX2019009443A (es
Inventor
Carolyn Luscombe
Gary Ewart
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of MX2019009443A publication Critical patent/MX2019009443A/es
Publication of MX387115B publication Critical patent/MX387115B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al tratamiento o prevención de infección por el virus de la influenza. En particular, la presente invención se refiere al uso de N-carbamimidoil-5-(1-metil- 1H-pirazol-4-il)-2-naftamida, o una sal farmacéuticamente aceptable de la misma, en el tratamiento o prevención de infección por el virus de la influenza.
MX2019009443A 2017-02-08 2018-02-07 Métodos para tratar la influenza. MX387115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (2)

Publication Number Publication Date
MX2019009443A MX2019009443A (es) 2019-12-16
MX387115B true MX387115B (es) 2025-03-19

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009443A MX387115B (es) 2017-02-08 2018-02-07 Métodos para tratar la influenza.

Country Status (13)

Country Link
US (1) US10918623B2 (es)
EP (1) EP3579833B1 (es)
JP (1) JP7019727B2 (es)
KR (1) KR102607599B1 (es)
CN (1) CN110325187B (es)
AU (1) AU2018218179B2 (es)
BR (1) BR112019016316A2 (es)
CA (1) CA3052503A1 (es)
ES (1) ES2910136T3 (es)
MX (1) MX387115B (es)
RU (1) RU2769317C2 (es)
SG (1) SG11201907034PA (es)
WO (1) WO2018145148A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5969471B2 (ja) 2010-07-22 2016-08-17 ギリード・サイエンシズ・インコーポレーテッド パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN114366745A (zh) 2015-09-16 2022-04-19 吉利德科学公司 治疗沙粒病毒科和冠状病毒科病毒感染的方法
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
CN110636884B (zh) 2017-05-01 2022-10-04 吉利德科学公司 新结晶形式
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
KR102906891B1 (ko) 2020-04-06 2026-01-05 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
JP2023531524A (ja) 2020-06-24 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシド類似体及びその使用
ES3015457T3 (en) 2020-08-24 2025-05-05 Gilead Sciences Inc Phospholipid compounds and uses thereof
AU2021331214B2 (en) 2020-08-27 2024-01-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
EP4346772A1 (en) 2021-05-26 2024-04-10 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023092180A1 (en) * 2021-11-24 2023-06-01 Biotron Limited Methods of treating sars-cov-2 infection
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
JP2025508943A (ja) 2022-03-02 2025-04-10 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
JP2025508941A (ja) 2022-03-03 2025-04-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物並びにその作製及び使用方法
CA3252494A1 (en) 2022-03-03 2023-09-07 Gilead Sciences, Inc. ANTIVIRAL COMPOUNDS AND THEIR MANUFACTURING AND USAGE PROCESSES
CA3257287A1 (en) 2022-06-06 2023-12-14 Gilead Sciences, Inc. METHODS OF TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-CoV-2
EP4547334A1 (en) 2022-06-29 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2025049699A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250099476A1 (en) 2023-09-06 2025-03-27 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564398A (en) * 2005-06-24 2011-11-25 Biotron Ltd 2-Naphthoyl-guanidine derivatives as antiviral agents
WO2009018609A1 (en) * 2007-08-03 2009-02-12 Biotrom Limited Hepatitis c antiviral compositions and methods
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
MX392650B (es) * 2014-07-07 2025-03-24 Elian Llc Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion
CN110870864B (zh) * 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Also Published As

Publication number Publication date
US20200093796A1 (en) 2020-03-26
RU2769317C2 (ru) 2022-03-30
EP3579833A1 (en) 2019-12-18
SG11201907034PA (en) 2019-08-27
CN110325187A (zh) 2019-10-11
US10918623B2 (en) 2021-02-16
EP3579833B1 (en) 2022-01-05
JP7019727B2 (ja) 2022-02-15
JP2020506243A (ja) 2020-02-27
NZ755900A (en) 2025-03-28
AU2018218179A1 (en) 2019-08-22
MX2019009443A (es) 2019-12-16
KR102607599B1 (ko) 2023-11-28
KR20190112051A (ko) 2019-10-02
WO2018145148A1 (en) 2018-08-16
ES2910136T3 (es) 2022-05-11
RU2019126746A3 (es) 2021-05-28
BR112019016316A2 (pt) 2020-03-31
EP3579833A4 (en) 2021-01-13
CA3052503A1 (en) 2018-08-16
CN110325187B (zh) 2022-09-30
RU2019126746A (ru) 2021-03-09
AU2018218179B2 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
MX387115B (es) Métodos para tratar la influenza.
EA201791576A1 (ru) Ингибитор jak
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
ZA201606320B (en) Human plasma kallikrein inhibitors
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201891644A1 (ru) Антибактериальные соединения и их применение
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX382765B (es) Tratamiento para la colangitis biliar primaria.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12016502322A1 (en) Compounds and methods for preventing or treating malaria
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX374354B (es) Método de curación de heridas.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA202190626A3 (ru) Комбинация тразодона и габапентина для лечения боли